Movantik

Chemical Namenaloxegol
Dosage FormTablet (oral; 12.5 mg, 25 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyRedHill Biopharma
Approval Year2014

Indication

  • For the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Movantik (naloxegol) Prescribing Information.2020RedHill Biopharma Inc., Raleigh, NC